CAJ | 학술논문

目的:检测视黄酸受体β2(RAR-β2)基因在不同乳腺肿瘤组织中的表达,探讨RAR-B2基因与乳腺肿瘤的关系,分析其在乳腺癌发生、发展中的作用.方法:免疫组织化学法检测乳腺浸润性癌、导管上皮重度不典型增生、腺纤维瘤各40例及20例正常乳腺组织中RAR-β2的表达情况.RT-PCR法检测乳腺浸润性癌、导管上皮重度不典型增生、腺纤维瘤及正常乳腺组织各20例RAR-β2的表达水平.结果:免疫组化结果显示,RAR-β2阳性表达主要位于细胞核,RAR-β2蛋白在乳腺浸润癌组织中阳性表达率(30.0%)明显低于正常乳腺组织(95.0%),x~2=26.30,P<0.05.PAR-β2蛋白在乳腺重度不典型增生组织中阳性表达率(17.5%)低于乳腺癌组织,但差异无统计学意义(P>0.05).在乳腺浸润性癌组织中,BAR-β2表达与患者年龄、肿瘤大小、临床分期、腋下淋巴结转移状况、组织学分级、病理学类型以及ER、PR表达状况无相关性(P均>0.05).随访结果显示,28例RAR-β2阴性乳腺癌患者中3例发生内脏转移,而12例RAR-β2阳性患者仅1例发生骨转移.RT-PCR结果显示,PAR-β2在乳腺癌、导管上皮重度不典型增生、腺纤维瘤及正常乳腺组织中阳性表达率分别为25.0%(5/20)、35.0%(7/20)、85.0%(17/20)和100%(20/20),乳腺癌组织RAR-β2mRNA明显低于正常乳腺组织(x~2=30.43,P<0.001).结论:RAR-β2可能在乳腺癌的发生过程中发挥抑制作用,并且可能在乳腺癌发生的早期发挥作用.
목적:검측시황산수체β2(RAR-β2)기인재불동유선종류조직중적표체,탐토RAR-B2기인여유선종류적관계,분석기재유선암발생、발전중적작용.방법:면역조직화학법검측유선침윤성암、도관상피중도불전형증생、선섬유류각40례급20례정상유선조직중RAR-β2적표체정황.RT-PCR법검측유선침윤성암、도관상피중도불전형증생、선섬유류급정상유선조직각20례RAR-β2적표체수평.결과:면역조화결과현시,RAR-β2양성표체주요위우세포핵,RAR-β2단백재유선침윤암조직중양성표체솔(30.0%)명현저우정상유선조직(95.0%),x~2=26.30,P<0.05.PAR-β2단백재유선중도불전형증생조직중양성표체솔(17.5%)저우유선암조직,단차이무통계학의의(P>0.05).재유선침윤성암조직중,BAR-β2표체여환자년령、종류대소、림상분기、액하림파결전이상황、조직학분급、병이학류형이급ER、PR표체상황무상관성(P균>0.05).수방결과현시,28례RAR-β2음성유선암환자중3례발생내장전이,이12례RAR-β2양성환자부1례발생골전이.RT-PCR결과현시,PAR-β2재유선암、도관상피중도불전형증생、선섬유류급정상유선조직중양성표체솔분별위25.0%(5/20)、35.0%(7/20)、85.0%(17/20)화100%(20/20),유선암조직RAR-β2mRNA명현저우정상유선조직(x~2=30.43,P<0.001).결론:RAR-β2가능재유선암적발생과정중발휘억제작용,병차가능재유선암발생적조기발휘작용.
Objective: To assess the expression of retinoic acid receptor beta 2 (RAR-β2) in breast tumor and to evaluate the relationship between RAR-β2 expression and tumorigenesis of breast cancer. Methods: Immu-nohistochemistry was used to detect the expression of RAR-β2 protein in specimens from 40 cases of breast cancer, 40 cases of atypical ductal hyperplasia, 40 cases of fibroadenoma and 20 cases of normal breast tissues. Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the mRNA expression levels of RAR-β2 gene in 20 cases of breast cancer, 20 cases of atypical ductal hyperplasia, 20 cases of fibroadenoma, and 20 cases of normal breast tissues. Results: Immunohistochemical staining results revealed that the positive expression of RAR-β2 protein showed nuclear staining. The positive expression rate of RAR-β2 was 30% (12/40) in breast cancer, 17.5% (7/40) in atypical ductal hyperplasia, 87.5% (35/40)in fibroadenoma, and 95% (19/20) in normal breast tissues. The expression of RAR-β2 protein in breast cancer was significantly lower than that in normal breast tissues (X~2=26.30, P<0.001). The expression of RAR-β2 was not significantly different between atypical ductal hyperplasia and breast cancer (P>0.05). No correlation was found between the expression of RAR-β 2 protein and the tumor size, menopausal age, lymph node metastasis, clinical stage, histological grade, or protein expression of ER and PR in breast cancer tissues (P>0.05). Follow-up results showed that 3 out of 28 patients with negative RAR-β2 expression had visceral organ metastasis, but only one of the 12 RAR-β2 positive patients had osseous metastasis. RT-PCR analysis showed that the positive expression rate of RAR-β2 mRNA in breast cancer, atypical ductal hyperplasia, fibroadenoma and normal breast tissues was 25% (5/20), 35% (7/20), 85% (17/20) and 100% (20/20), respectively. The RAR-β2 mRNA expression rate in breast cancer was significantly lower than that in normal breast tissues (X~2=30.43, P<0.001). No significant difference in RAR-β2 mRNA expression was found between atypical ductal hyperplasia and breast cancer tissues (P>0.05). Conclusion: RAR-β2 gene may play a repressive role in the initiation of breast cancer, and the loss of the expression of RAR-β2 gene may be the initial step in breast carcinogenesis.